Sino BiologicalInc.
Sino Biological,Inc. provides recombinant protein and antibody reagents for life science researchers in China and internationally. The company offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents. It also provides comprehensive solutions, including autoimmune disease research, kinase drug discover… Read more
Sino BiologicalInc. (301047) - Total Assets
Latest total assets as of June 2025: CN¥5.94 Billion CNY
Based on the latest financial reports, Sino BiologicalInc. (301047) holds total assets worth CN¥5.94 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sino BiologicalInc. - Total Assets Trend (2019–2024)
This chart illustrates how Sino BiologicalInc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sino BiologicalInc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Sino BiologicalInc.'s total assets of CN¥5.94 Billion consist of 69.5% current assets and 30.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.9% |
| Accounts Receivable | CN¥150.48 Million | 2.5% |
| Inventory | CN¥64.40 Million | 1.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥44.79 Million | 0.7% |
| Goodwill | CN¥278.38 Million | 4.6% |
Asset Composition Trend (2019–2024)
This chart illustrates how Sino BiologicalInc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sino BiologicalInc.'s current assets represent 69.5% of total assets in 2024, an increase from 62.5% in 2019.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2024, down from 5.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 4.6% of total assets.
Sino BiologicalInc. Competitors by Total Assets
Key competitors of Sino BiologicalInc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Sino BiologicalInc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Sino BiologicalInc. generates 0.10x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Sino BiologicalInc. generates $ 2.01 in net profit.
Sino BiologicalInc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 30.85 | 25.57 | 65.12 |
| Quick Ratio | 30.22 | 25.20 | 64.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.88 Billion | CN¥ 4.28 Billion | CN¥ 6.05 Billion |
Sino BiologicalInc. - Advanced Valuation Insights
This section examines the relationship between Sino BiologicalInc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.69 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -8.3% |
| Total Assets | CN¥6.05 Billion |
| Market Capitalization | $400.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sino BiologicalInc.'s assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sino BiologicalInc.'s assets decreased by 8.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sino BiologicalInc. (2019–2024)
The table below shows the annual total assets of Sino BiologicalInc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.05 Billion | -8.27% |
| 2023-12-31 | CN¥6.60 Billion | +0.31% |
| 2022-12-31 | CN¥6.58 Billion | -4.50% |
| 2021-12-31 | CN¥6.89 Billion | +362.96% |
| 2020-12-31 | CN¥1.49 Billion | +695.25% |
| 2019-12-31 | CN¥187.15 Million | -- |